Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Oral Suspension in Pediatric NDO or OAB
NCT02526979Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mirabegron in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration of Mirabegron, Area Under the Concentration-Time Curve from Time Zero to Infinity and 2 more. Started Dec 2015; status: completed.
02
Drugs
mirabegron
03
Conditions
neurogenic detrusor overactivity (NDO)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02526979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526979.